<DOC>
	<DOCNO>NCT02165397</DOCNO>
	<brief_summary>The purpose study evaluate safety efficacy Ibrutinib combination Rituximab subject Waldenström 's Macroglobulinemia .</brief_summary>
	<brief_title>Ibrutinib With Rituximab Adults With Waldenström 's Macroglobulinemia</brief_title>
	<detailed_description />
	<mesh_term>Waldenstrom Macroglobulinemia</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>Eligibility Criteria Randomized Study ( Arm A Arm B ) Untreated previously treat Waldenström 's macroglobulinemia . Previously treated subject must either documented disease progression response ( stable disease ) recent treatment regimen . Centrally confirm clinicopathological diagnosis WM Measurable disease define serum monoclonal IgM &gt; 0.5 g/dL . Symptomatic disease meeting least 1 recommendation Second International Workshop Waldenström Macroglobulinemia require treatment Hematology biochemical value within protocoldefined limit Men woman ≥ 18 year age . Eastern Cooperative Oncology Group ( ECOG ) performance status ≤2 . Known involvement central nervous system WM . Disease refractory last prior rituximabcontaining therapy define either Relapse last rituximabcontaining therapy &lt; 12 month since last dose rituximab , OR Failure achieve least MR last rituximabcontaining therapy . If subject meet exclusion criterion therefore exclude main randomized study , participation non randomize substudy ( Arm C ) may consider Rituximab treatment within last 12 month first dose study drug . Known anaphylaxis IgEmediated hypersensitivity murine proteins component rituximab . Prior exposure ibrutinib BTK inhibitor . Known bleed disorder ( eg , von Willebrand 's disease ) hemophilia . History stroke intracranial hemorrhage within 12 month prior enrollment . Any uncontrolled active systemic infection . Any lifethreatening illness , medical condition , organ system dysfunction , investigator 's opinion , could compromise subject 's safety put study outcome undue risk . Currently active , clinically significant cardiovascular disease Requires treatment strong cytochrome P450 ( CYP ) 3A inhibitor Eligibility Criteria Openlabel Substudy Treatment Arm C The Inclusion/Exclusion criterion substudy ( Arm C ) identical describe randomize study , eligible , subject need consider refractory last prior rituximabcontaining therapy define either Relapse last rituximabcontaining therapy &lt; 12 month since last dose rituximab , OR Failure achieve least MR last rituximabcontaining therapy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Ibrutinib</keyword>
	<keyword>Pharmacyclics</keyword>
	<keyword>PCYC</keyword>
	<keyword>Lymphoma</keyword>
	<keyword>Btk inhibitor</keyword>
	<keyword>WM</keyword>
	<keyword>Rituximab</keyword>
	<keyword>Rituxan</keyword>
	<keyword>Waldenström 's</keyword>
	<keyword>Waldenstrom Macroglobulinemia</keyword>
	<keyword>non-Hodgkin lymphoma</keyword>
	<keyword>NHL</keyword>
</DOC>